Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit

Trial Profile

A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2022

At a glance

  • Drugs Immune globulin (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Grifols
  • Most Recent Events

    • 10 Nov 2021 Status changed from active, no longer recruiting to completed.
    • 09 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Aug 2021.
    • 09 Aug 2021 Status changed from recruiting to active, no longer recruiting.

Trial Overview

Purpose

The purpose of the study is to determine if a high dose of Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) can reduce all-cause mortality versus SMT alone in hospitalized participants with COVID-19 requiring admission to the ICU through Day 29.

Primary Endpoints

All-Cause Mortality Rate Through Day 29

description: All-cause mortality rate is percentage of participants in each treatment group who experienced mortality up to Day 29.
time_frame: Up to Day 29

Other Endpoints

Percentage of Participants With Actual Intensive Care Unit (ICU) Discharge Time

description: Percentage of participants who were discharged from ICU were recorded. Time to actual ICU discharge was defined as duration of actual ICU stay from Day 1 through Day 29.
time_frame: Up to Day 29

Duration of Mechanical Ventilation

description: Duration (number of days) of ICU stay from post-randomization through Day 29 was calculated based on ICU admission and discharge (actual and medical equivalence) dates.
time_frame: Up to Day 29

Percentage of Participants With Actual Hospital Discharge Time

description: Percentage of participants who were discharged from the hospital were recorded. Time to hospital discharge was defined as duration of hospitalization from Day 1 through Day 29.
time_frame: Up to Day 29

Duration of Any Oxygen Use From Day 1 Through Day 29

description: Duration (number of days) of any oxygen use from Day 1 through Day 29 was calculated based on the start/stop dates.
time_frame: Up to Day 29

Mean Change From Baseline in Ordinal Scale

description: The ordinal scale is a 7-point scale ranging from 1 to 7 used to measure clinical status based on the following points: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. Higher score indicated no severe illness. Mean change in Ordinal scale was evaluated by fitting a linear mixed-effects model for repeated measures (MMRM). The data is reported for average across all postbaseline.
time_frame: Baseline up to Day 29

Absolute Change From Baseline in Ordinal Scale at Day 29

description: The ordinal scale is a 7-point scale ranging from 1 to 7 used to measure clinical status based on the following points: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. Higher score indicated no severe illness.
time_frame: Baseline, Day 29

Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale

description: The ordinal scale is a 7-point scale ranging from 1 to 7 used to measure clinical status based on the following points: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.
time_frame: Days 15 and 29

Percentage of Participants Who Develop Acute Respiratory Distress Syndrome (ARDS)

description: Acute Respiratory Distress Syndrome was defined based on Berlin criteria (chest imaging, origin of edema, oxygenation).
time_frame: Days 1, 5, 15 and 29

Percentage of Participants Who Develop ARDS Distributed by Severity

description: ARDS was defined by Berlin's criteria as: 1) Timing is usually within 1 week of a known clinical insult or new or worsening respiratory symptoms 2) Chest imaging: bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules 3) Respiratory failure not fully explained by cardiac failure or fluid overload Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present 4) Oxygenation: Mild 200 mm Hg < partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ≤ 300 mm Hg with positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) ≥ 5 cm H2Oc; Moderate 100 mm Hg < PaO2/FIO2 ≤ 200 mm Hg with PEEP ≥ 5 cm H2O; Severe PaO2/FIO2 ≤100 mm Hg with PEEP ≥ 5 cm H2O.
time_frame: Days 1, 5, 15 and 29

Change From Baseline in Sequential Organ Failure Assessment (SOFA) Score at Day 5, Day 15, and Day 29

description: SOFA score is a mortality prediction score that is based on the degree of dysfunction of six organ systems. The score is calculated on admission and every 24 hours until discharge using the worst parameters measured during the prior 24 hours SOFA score ranges from 0 (no organ dysfunction) to 24 (highest possible score / organ dysfunction). Higher score indicated severe illness.
time_frame: Days 5, 15, and 29

Change From Baseline in National Early Warning Score (NEWS)

description: NEWS is clinical scoring developed to improve detection of deterioration in ill participant. It is based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure (BP), pulse rate, level of consciousness, and temperature. A score of 0 and 2 was allocated to supplemental oxygen, 0 and 3 for level of consciousness and score of 0, 1, 2 and 3 for remaining parameters (i.e. respiration rate, oxygen saturation, systolic BP, pulse rate and temperature) where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS score ranged from 0 to 20, with higher scores meaning more severity/higher risk.
time_frame: Baseline and Day 29

Percentage of Participants Achieving Clinical Response: NEWS ≤ 2 Maintained for 24 Hours

description: Percentage of participants who achieved clinical response (i.e the NEWS score ≤2 maintained for 24 hours from Day 1 through Day 29) was estimated using the Kaplan-Meier method.
time_frame: Day 29 [1]

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Biomarker

NCT Number Biomarker Name Biomarker Function
NCT04480424 C-reactive protein (CRP) Eligibility Criteria
D-dimer Eligibility Criteria
Factor V Eligibility Criteria
Ferritin Eligibility Criteria
Prothrombin (PT) Eligibility Criteria
For more detail, check out BiomarkerBase: the leading source of information about biomarkers used in drug development and diagnostic tests, tracking a comprehensive list of biomarker uses worldwide by over 800 companies

Subjects

  • Subject Type patients
  • Number

    Planned: 100

    Actual: 100

  • Sex male & female
  • Age Group ≥ 18 years; adult

Patient Inclusion Criteria

- Hospitalized male or female subjects of ≥ 18 years of age at time of Screening who are being treated in the ICU for COVID-19 for not longer than 48 hours or for whom a decision has been made that COVID-19 disease severity warrants ICU admission. - Has laboratory-confirmed novel coronavirus {SARS-CoV-2} infection as determined by qualitative polymerase chain reaction (PCR) (reverse transcriptase [RT]-PCR), or other United States Food and Drug Administration (FDA)-approved diagnostic assay for COVID-19 in any specimen during the current hospital admission prior to randomization. - Illness (symptoms of COVID-19 of any duration requiring ICU level care), and the following: 1. Radiographic infiltrates by imaging (chest X-Ray, computerized tomography (CT) scan, etc.), and 2. Requiring mechanical ventilation and/or supplemental oxygen. - Any one of the following related to COVID-19: i. Ferritin > 400 nanogram per milliliter (ng/mL), ii. Lactate dehydrogenase (LDH) > 300 units per liter (U/L), iii. D-Dimers > reference range, or iv. C-reactive protein (CRP) > 40 milligram per liter (mg/L). - Subject provides informed consent prior to initiation of any study procedures.

Patient Exclusion Criteria

- Clinical evidence of any significant acute or chronic disease or pathophysiologic manifestations (eg, complications of COVID-19 standard medical treatments) that, in the opinion of the investigator, may place the subject at undue medical risk. - The subject has had a known (documented) serious anaphylactic reaction to blood, any blood-derived or plasma product or a past history of any hypersensitivity reactions to commercial immunoglobulin. - A medical condition in which the infusion of additional fluid is contraindicated. - Shock that is unresponsive to fluid challenge and/or multiple vasopressors and accompanied by multiorgan failure considered by the Principal Investigator not able to be reversed. - Subjects with known (documented) thrombotic complications to polyclonal IVIG therapy in the past. - Subjects with current or prior myocardial infarction, stroke, deep vein thrombosis, or thromboembolic event (within the past 12 months) or who have a history of thromboembolic events of unknown etiology. - Subjects with limitations of therapeutic effort. - Female subjects who are pregnant or of child-bearing potential with a positive test for pregnancy blood or urine human chorionic gonadotropin (HCG)-based assay at Screening/Baseline. - Subjects participating in another interventional clinical trial with investigational medical product or device. - Known history of prothrombin gene mutation 20210, homozygous Factor V Leiden mutations, antithrombin III deficiency, protein C deficiency, protein S deficiency or antiphospholipid syndrome. - Presence of malignancy (either new diagnosis of malignancy or known residual disease) within the past 12 months. - Creatinine at Screening is ≥ 4 mg/dL (or subject is dependent on dialysis/renal replacement therapy). - Known Immunoglobulin A (IgA) deficiency with anti-IgA serum antibodies. - Uncontrolled hypertension at the time of Screening (systolic blood pressure > 200 mm Hg) or refractory severe hypotension with sustained systolic blood pressure < 90 mm Hg unresponsive to vasopressors.

Trial Details

Identifiers

Identifier Owner
NCT04480424 ClinicalTrials.gov: US National Institutes of Health
GC2007 -

Organisations

  • Sponsors Grifols
  • Affiliations Grifols

Trial Dates

  • Initiation Dates

    Planned : 01 Jul 2020

    Actual : 17 Sep 2020

  • Primary Completion Dates

    Planned : 01 Aug 2021

    Actual : 25 Aug 2021

  • End Dates

    Planned : 01 Oct 2021

    Actual : 25 Oct 2021

Other Details

  • Design multicentre; open; parallel; prospective; randomised
  • Phase of Trial Phase II
  • Location USA
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
Immune globulinPrimary Drug Intravenous Infusion

GAMUNEX-C + Standard Medical Treatment

Participants received 2 grams per kilogram (g/kg) of GAMUNEX-C, which was capped to a maximum of 160 g infusion intravenously (IV) for participants weighing more than 80 kg on Day 1. The 2 g/kg net total dose was divided either into infusions of 500 mg/kg body weight over 4 days or 400 mg/kg body weight over 5 days as per investigator's decision. Participants received standard of care interventions as per Principal Investigator's discretion from Day 1 up to Day 29. Biological: GAMUNEX-C (Intravenous Immune Globulin (Human), 10% Caprylate/Chromatography Purified.) Other Name: IGIV-C Drug: Standard Medical Treatment (SMT per local policies or guidelines.)

Standard Medical Treatment

Participants received all standard of care interventions required as per Principal Investigator's discretion throughout the participant's hospitalization, from Day 1 to Day 29. Drug: Standard Medical Treatment (SMT per local policies or guidelines.)

Trial Centres

Investigators

Investigator Centre Name Trial Centre Country
Christopher Provenzano, MD McLaren Health Care-Macomb USA
Daniel Coulston, MD MultiCare Deaconess Hospital USA
Elsa Mondou, MD
919-316-2079 elsa.mondou@grifols.com
show details
-
Franklin Rosenblat, MD McLaren Health Care Oakland USA
Gerard Criner, MD Temple University Hospital USA
John Youssef, MD McLaren Flint USA
Kristopher Roach, MD Chandler Regional Medical Center USA
Leon Tung, MD CHRISTUS Health USA
Margaret Hagan, MD Via Christi Research USA
Michael Tan, MD Summa Health USA
Mohamed Saad, MD University of Louisville USA
Monica Goldklang, MD Columbia University Medical Center USA
Patricia Finn, MD University of Illinois at Chicago USA
Rhonda Griffin
919-316-6693 rhonda.griffin@grifols.com
show details
-
Robert Plambeck, MD CHI Health USA
Simon Mahler, MD Wake Forest Baptist Medical Center USA
Steven Conrad, MD Louisiana State University Health Sciences Center USA
Tarek Hassanein, MD Southern California Research Center USA
Tiffany Dumont, MD Allegheny Health Network Research Institute USA

Centres

Centre Name Location Trial Centre Country
-
-
-
Allegheny Health Network Research Institute Pittsburgh, Pennsylvania USA
Chandler Regional Medical Center Chandler, Arizona USA
CHI Health Omaha, Nebraska USA
CHRISTUS Health Tyler, Texas USA
Columbia University Medical Center New York, New York USA
Grifols Therapeutics LLC
-
-
Louisiana State University Health Sciences Center Shreveport, Louisiana USA
McLaren Flint Flint, Michigan USA
McLaren Health Care Oakland Pontiac, Michigan USA
McLaren Health Care-Macomb Mount Clemens, Michigan USA
MultiCare Deaconess Hospital Spokane, Washington USA
MultiCare Tacoma General Hospital Tacoma, Washington USA
Southern California Research Center Coronado, California USA
Summa Health Akron, Ohio USA
Temple University Hospital Philadelphia, Pennsylvania USA
University of Illinois at Chicago Chicago, Illinois USA
University of Louisville Louisville, Kentucky USA
Via Christi Research Wichita, Kansas USA
Wake Forest Baptist Medical Center Winston-Salem, North Carolina USA

Trial History

Event Date Event Type Comment
10 Oct 2022 Other trial event Last checked against Clinicaltrials.gov record. Updated 10 Oct 2022
10 Nov 2021 Status change - completed Status changed from active, no longer recruiting to completed. Updated 15 Nov 2021
10 Aug 2021 Biomarker Update Biomarkers information updated Updated 04 Nov 2021
09 Aug 2021 Other trial event Planned primary completion date changed from 1 Jul 2021 to 1 Aug 2021. Updated 12 Aug 2021
09 Aug 2021 Status change - active, no longer recruiting Status changed from recruiting to active, no longer recruiting. Updated 12 Aug 2021
30 Apr 2021 Completion date Planned End Date changed from 1 May 2021 to 1 Oct 2021. Updated 04 May 2021
30 Apr 2021 Other trial event Planned primary completion date changed from 1 Apr 2021 to 1 Jul 2021. Updated 04 May 2021
12 Nov 2020 Completion date Planned End Date changed from 1 Feb 2021 to 1 May 2021. Updated 18 Nov 2020
12 Nov 2020 Other trial event Planned primary completion date changed from 1 Dec 2020 to 1 Apr 2021. Updated 18 Nov 2020
21 Sep 2020 Status change - recruiting Status changed from not yet recruiting to recruiting. Updated 24 Sep 2020
23 Jul 2020 Other trial event New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT04480424). Updated 23 Jul 2020
21 Apr 2020 Other trial event According to a Grifols media release, the company is leading this trial in collaboration with the U.S. Food and Drug Administration (FDA) and other health agencies. Updated 22 Apr 2020
30 Mar 2020 New trial record New trial record Updated 30 Mar 2020
25 Mar 2020 Other trial event According to a Grifols media release, the company will is collaborating with certain hospitals in the design of this study. Updated 30 Mar 2020

References

  1. ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2023;.

    Available from: URL: http://clinicaltrials.gov
  2. Grifols. Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19. Media-Rel 2020;.

    Media Release
  3. Grifols. Grifols maintains its operational levels and continues to reinforce its commitment to society. Media-Rel 2020;.

    Media Release
Back to top